PD-1: Clinical Trials

7 trials for PD-1, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 unknown. 7 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 27Unknown 7
Phase 11Unknown 1

Follow PD-1: new trials by email Literature Review of PD-1 trials Research Report on PD-1

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
LM-108 antibody and sintilimab, LM-108 antibody and sintilimab and chemotherapy - NSCLC, PD-1
Phase 2UnknownShanghai Pulmonary Hospital, Shanghai, China502024-01-122024-06-28
RC48 Combined With Toripalimab and Radiotherapy for Bladder Sparing Treatment in MIBC
Disitamab Vedotin and Toripalimab - Muscle Invasive Bladder Cancer, HER2 Expression
Phase 2UnknownRenJi Hospital62023-08-012023-08-31
A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
F520, Pemetrexed, Carboplatin - Non-small Cell Lung Cancer, NSCLC
Phase 2UnknownShandong New Time Pharmaceutical Co., LTD842023-03-012023-02-24
A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study
Tislelizumab - Head and Neck Cancer, Radiation
Phase 2UnknownShanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University382021-04-012021-03-24
Neoadjuvant Sintilimab Plus Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction
PD-1inhibitor - PD-1, Neoadjuvant Chemoradiotherapy
Phase 2UnknownUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology322021-03-302024-02-09
PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC
PD-1 plus Dasatinib - NSCLC Stage IV, ARID1A
Phase 2UnknownThe Affiliated Hospital of Qingdao University302020-03-012020-02-25
Toripalimab With Preoperative Chemoradiotherapy for LA-EGJ
PD-1 - PD-1, Chemoradiotherapy
Phase 1 / Phase 2UnknownPeking University452019-08-262019-08-20

Narrower conditions

Carcinoma, Non-Small-Cell Lung (2)  ·  Head and Neck Neoplasms (1)

Broader conditions

Neoplasms (3)  ·  Neoplasms by Site (3)  ·  Bronchial Neoplasms (2)  ·  Carcinoma, Bronchogenic (2)  ·  Lung Diseases (2)  ·  Lung Neoplasms (2)  ·  Respiratory Tract Diseases (2)  ·  Respiratory Tract Neoplasms (2)  ·  Thoracic Neoplasms (2)

Interventions

toripalimab (2)  ·  Carboplatin (1)  ·  Dasatinib (1)  ·  Drug Therapy (1)  ·  Paclitaxel (1)  ·  Pemetrexed (1)  ·  RC48 antibody (1)  ·  disitamab vedotin (1)  ·  sintilimab (1)  ·  tislelizumab (1)

Sponsors

Peking University (1)  ·  RenJi Hospital (1)  ·  Shandong New Time Pharmaceutical Co., LTD (1)  ·  Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1)  ·  Shanghai Pulmonary Hospital, Shanghai, China (1)  ·  The Affiliated Hospital of Qingdao University (1)  ·  Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1)

Countries

China (5)

Top investigators

Chunxia Su, Phd (1)  ·  Haige Chen (1)  ·  Yongheng Li, MD (1)  ·  Ziyu Li, MD (1)

Results publications

PMID 40774226